SAN DIEGO — Among patients with skin of color and moderate to severe atopic dermatitis (AD) who underwent 16 weeks of treatment with lebrikizumab, 68% achieved a 75% reduction in the Eczema Area and Severity Index (EASI-75), interim results from a novel phase 3b trial showed. Lebrikizumab, a novel monoclonal antibody being developed by Eli...
Category: <span>Pharmaceutical Updates</span>
Post
Tirzepatide found to reduce body weight, waist circumference in those with obesity regardless of duration of condition
by European Association for the Study of Obesity Credit: CC0 Public DomainNew research to be presented at this year’s European Congress on Obesity (Venice, Italy, May 12-15) shows that the obesity medication tirzepatide consistently reduces body weight and waist circumference regardless of the length of time the person has been living with overweight or obesity....
Post
Alzheimer’s drug fermented with help from AI and bacteria moves closer to reality
An innovative approach uses artificial intelligence and biosensors to pave the way for faster drug development Peer-Reviewed PublicationUNIVERSITY OF TEXAS AT AUSTIN IMAGE: AN ALZHEIMER’S DRUG USUALLY HARVESTED FROM DAFFODILS IS ONE STEP CLOSER TO BEING FERMENTED INSIDE BACTERIA THANKS TO SOME HELP FROM ARTIFICIAL INTELLIGENCE AND BIOSENSORS. view moreCREDIT: PHOTO-ILLUSTRATION: MARTHA MORALES/THE UNIVERSITY OF...
Post
FDA approves Madrigal’s NASH drug, marking the first-ever treatment for the liver disease
FDA approves Madrigal’s NASH drug, marking the first-ever treatment for the liver diseaseNicole DeFeudisEditorMadrigal Pharmaceuticals’ NASH drug won an accelerated approval on Thursday, becoming the first treatment for a liver disease that for years has vexed scientists and investors. The medication, resmetirom, was approved under the brand name Rezdiffra for patients with stage 2 and...
Post
New nasal spray may reduce severity of sleep apnea, researchers find
by Flinders University Using a bedtime nasal spray that activates throat muscles can reduce the severity of sleep apnea and lower blood pressure. Credit: Flinders UniversityAustralian researchers have discovered that a bedtime nasal spray has the potential to reduce the severity of sleep apnea in people and lower their blood pressure. The new research published...
Post
Diet and Exercise in a Pill Are Real: How Mimetics Work
Sari Harrar If couch-potato lab mice had beach-body dreams and if they could speak, they might tell you they’re thrilled by advances in the science of exercise and calorie-restriction (CR) mimetics. In recent studies conducted at research centers across the United States, mice have chowed down, fattened up, exercised only if they felt like it,...
Post
New dual therapeutic strategy shows promise against multidrug-resistant Salmonella
by University of Eastern Finland Quinazoline CA439 enhances the action of the antimicrobial peptide colistin through a triple mechanism of action that involves: 1, permeabilization of the bacterial outer membrane; 2, down-regulation of polymyxin resistance genes through the PhoP/PhoQ-PmrA/PmrB cascade; 3, alteration of electrochemical potential of the bacterial inner membrane. Credit: C. Asquith.A new collaborative...
Post
Frexalimab Promising for Relapsing Multiple Sclerosis
Megan Brooks Frexalimab (Sanofi), a novel, investigational second-generation inhibitor of the CD40 ligand, significantly reduced disease activity in relapsing multiple sclerosis (MS) and was well tolerated in a phase 2 study. At week 12, there was an 89% reduction in new gadolinium (Gd)-enhancing T1 brain lesions — a standard measure of active inflammation in MS...
Post
No End in Sight for National ADHD Drug Shortage
Alicia Ault Nearly 18 months after the US Food and Drug Administration (FDA) first acknowledged a national shortage of Adderall, the most common drug used to treat attention-deficit/hyperactivity disorder (ADHD), there is now a widespread scarcity of other stimulant medications — with no end in sight. How did this crisis develop and what measures are...
Post
Long-acting injectable ART superior to standard care for poorly adherent people with HIV
by Elana Gotkine For people with HIV (PWH) and a history of suboptimal adherence to antiretroviral therapy, long-acting injectable treatment with cabotegravir and rilpivirine (LAI) is superior to oral standard of care (SOC), according to a study presented at the annual Conference on Retroviruses and Opportunistic Infections, held from March 3 to 6 in Denver....